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ABSTRACT 
Objective: We aimed to examine the impact of  HF on stroke mortality and recurrence (in-
hospital and post-discharge) in a national stroke cohort from Thailand. 
Methods: We utilised a large insurance-based database including all stroke admissions in the 
public health sector in Thailand between 2004 and 2015. Logistic and Royston-Parmar 
regressions were used to quantify the effect of HF on in-hospital and long-term outcomes, 
respectively. All models were adjusted for age, sex and and co-morbidities and stratified by 
stroke type: Acute Ischaemic Stroke (AIS) or Intracerebral Haemorrhage (ICH). Multi-state 
models were constructed using flexible survival techniques to predict the impact of HF on the 
disease course of a stroke patient (baseline-(recurrence)-death). Only first-ever cases of AIS 
or ICH were included in the multi-state analysis.  
Results: 608,890 patients (mean age 64.29±13.72 years, 55.07% men) were hospitalised 
(370,527 AIS, 173,236 ICH and 65,127 Undetermined pathology). There were 398,663 first-
ever AIS and ICH patients. Patients were followed up for a median (95%CI) of 4.47 years 
(4.45 – 4.49). HF was associated with an increase in post-discharge mortality in AIS 
(HR[99%CI]=1.54[1.48-1.61]) and ICH (2.10[1.47-3.00]). HF was associated with AIS 
recurrence (1.46 [1.08-1.98]) in those surviving beyond 8 months, whilst ICH recurrence was 
only significantly increased within first 18 months (2.01 [1.19-3.40]).  
Conclusions: HF increases the risk of mortality in both AIS and ICH.  We are the first to 
report on high-risk periods of stroke recurrence in HF patients with ICH. Specific targeted 
risk reduction strategies may have significant clinical impact for mortality and recurrence in 
stroke.  
Key Words: Heart Failure, Cerebrovascular Disorders, Brain Infarction, Cerebral 
Haemorrhage  
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KEY QUESTIONS 
What is already known about this subject? 
• Heart failure is associated with higher mortality and recurrence rates after ischaemic 
stroke 
• Previous literature results are based solely on Western populations 
What does this study add? 
• This is the first study to examine this relationship in an Asian stroke population 
• Heart failure predicts higher mortality outcomes not only in ischaemic, but also in 
haemorrhagic stroke patients 
• Heart failure is only associated with higher recurrence rates in the short-term follow-
up for both stroke types 
How might this impact on clinical practice? 
• Clinicians should be aware that both ischaemic and haemorrhagic stroke patients with 
heart failure are at higher risk of both mortality and recurrence in the short-term (up to 
2 years) 
• This study should be replicated in other Asian populations 
 
INTRODUCTION 
 
Heart failure (HF) is a recognized risk factor for stroke incidence. The proposed 
mechanisms underlying the association between HF and increased risk of acute ischemic 
stroke (AIS) include thromboembolism, cerebral hypoperfusion and small vessel endothelial 
damage [1]. The association between HF and ICH is less clearly understood, but may relate 
to antithrombotic therapy being administered in patients with HF, particularly in those with 
ischaemic cardiomyopathy or AF [2].   
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Given the increased stroke incidence in HF patients, hypotheses regarding the influence 
of pre-existing HF on acute stroke outcomes have been formulated [3]. Previous studies have 
mainly analysed the association between prevalent HF and post-AIS outcomes, suggesting 
that it may be associated with higher mortality, longer in-hospital stay and higher disability 
and recurrence rates [1, 4-8]. Nevertheless, there have been no studies evaluating the impact 
of HF on the outcomes of intracerebral haemorrhage (ICH).  
In the current study, we sought to determine impact of HF on in-hospital and long-term 
outcomes (mortality and stroke-specific recurrence) in both major stroke subtypes (AIS and 
ICH) using a large unselected cohort of stroke patients. Identification of HF as a risk factor 
for stroke mortality and recurrence may drive further research for the identification and 
testing of targeted interventions in this population.  
 
METHODS 
Data acquisition, case ascertainment and variable coding 
 We utilised a large observational cohort of consecutively admitted stroke patients 
from Thailand, drawn from the Universal Coverage (UC) Health Insurance Database. Details 
regarding the health insurance systems in Thailand can be found in our previous reports [9, 
10]. Eligible patients were selected based on the primary diagnosis ICD10 (International 
Classification of Disease, tenth revision) code recorded in the database. All patients covered 
by the basic health insurance system ever admitted between October 2004 and September 
2015 with a diagnosis of stroke (ICD10 codes I61 (intracerebral haemorrhage), I63 (cerebral 
infarction), I64 (stroke of undetermined pathology)) were included in this study. Pre-existing 
co-morbidity, demographic and clinical data were extracted from insurance reimbursement 
forms using ICD10 codes, detailed in Supplementary Table 1. 
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Further admissions with a primary diagnosis of stroke or heart failure (ICD10) and the 
vital status (date of death if applicable) were recorded. A recurrent stroke event during the 
follow-up was extracted only if the primary diagnosis of this admission matched the one of 
the index stroke. In order to account for any new HF diagnoses, we also assessed subsequent 
hospital admissions, for any changes in the HF comorbidity status. Our study protocol 
conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Ethical approval was 
obtained from the Ethics Committee in Human Research, Khon Kaen University, Khon Kaen, 
Thailand. 
 
Inclusion criteria 
 Inclusion criteria, outcomes of interest (mortality and stroke recurrence) and selection 
of study variables were all determined a-priori. A total of 615,758 of stroke patients were 
admitted with primary diagnosis of stroke in the database. After excluding patients younger 
than 18 (n=1427) or older than 100 (n=43) and those with a missing post-discharge data 
(n=5419), a total of 608,890 acute stroke patients were included. 
 For the outcome of stroke recurrence, a further 81,530 patients with prevalent stroke 
(ICD10 I61, I63, I64) were excluded as well as 128,697 stroke patients who were diagnosed 
with a stroke of undetermined pathology on their index admission, yielding a cohort of 
398,663 first-ever AIS and ICH patients.  
 
Statistical Analysis 
 All analyses were performed using Stata 14.2 SE (StataCorp 2015), Stata Statistical 
Software. Due to the large sample size, we chose a P value <0.01 to represent the threshold of 
statistical significance. 
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Descriptive Statistics  
 Stroke type-specific descriptive characteristics were compared between those with 
prevalent HF and those without at the baseline (index admission in the database) using the 
independent-sample t-test, Mann-Whitney U test and Chi-squared test, as appropriate.  
 
  
Analysis of in-hospital mortality 
 Logistic regressions were used to examine the impact of HF on in-hospital mortality. 
We performed analyses for the entire cohort and then stratified by 3 categories (ischemic, 
haemorrhagic and stroke of undetermined pathology). In order to minimise confounding, we 
selected covariates according to previous literature [4-8] to be included in the multivariable 
logistic regression model. All models were adjusted for age, sex, co-morbidities 
(hypertension, diabetes mellitus, dyslipidaemia, ischaemic heart disease, valvular disease, 
atrial fibrillation, other arrhythmias, peripheral vascular disease, cancers, chronic obstructive 
pulmonary disease, liver disease, anaemia, alcohol-related disorders, neurodegenerative 
disorders) and admission parameters (fever, hypoglycaemia, hyperglycaemia). Additional 
sensitivity analyses were performed with adjustments limited to age, sex, cancer and 
important cardiovascular co-morbidities (hypertension, diabetes, hyperlipidaemia, ischaemic 
heart disease, valvular heart disease, atrial fibrillation, other arrhythmias, and peripheral 
vascular disease).  
 
Analysis of long-term post-discharge mortality 
 To examine the influence of HF on long term mortality, we constructed a survival 
model based on a flexible parametric regression [11], using restricted cubic splines (RCS). 
The number of internal knots was chosen pragmatically in line with existing literature [12, 
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13] for our sample size. The proportional hazards (PH) assumption was verified using log 
negative log plots. The hazard ratios (HR) for the variables which violated the PH assumption 
were modelled parametrically using the Weibull distribution. When HF was found violate the 
PH assumption, the HR was modelled using RCSs with 5 internal knots. Models were 
adjusted for the same confounders as above. Any new HF diagnosis after discharge was 
included as a binary time-updated variable in the models.  
 
Analysis of long-term post-discharge mortality and recurrence  
 We constructed 3 transition multi-state models illustrating the typical natural course 
of a stroke patient (Figure 1). This part of the analysis was confined to first-ever stroke cases, 
given that one of the outcomes of the multi-state model was stroke recurrence. Furthermore, 
only stroke cases with an identified stroke type (either AIS or ICH) were included. All 
models were adjusted for any post-discharge incident HF or any of the adjusting co-
morbidities. . Each transition was modelled using the same protocol as above. The simulation 
method [12] was employed to estimate the transition probabilities and their 99% confidence 
intervals. Models were adjusted for the same confounders as above. Additional sensitivity 
analyses with limited adjustments were performed for transitions 1 and 2. 
 
RESULTS 
Patient population & Descriptive Statistics  
 A flowchart of the patient population is illustrated in Figure 2. After applying the 
exclusion criteria, a total of 608,890 stroke cases were included. There were 370,527 
(60.85%) cases of AIS, 173,236 (28.45%) cases of ICH and 65,127 (10.70%) cases of stroke 
with an undetermined pathology.  
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 The patient characteristics on admission are summarised in Table 1. Patients had a 
mean age (SD) of 64.3 (13.7). There were 55.1% males. Patients with pre-existing HF 
(compared to those without) were older, more likely to be female, spend more time in 
hospital and have a higher co-morbidity burden across all stroke types. The admission 
parameters, in-hospital complications and procedures are summarised Table 2. Patients with 
pre-existing HF (compared to those without) were more likely to be hypoglycaemic on 
admission, die in hospital and suffer complications (respiratory failure, pneumonia, sepsis, 
shock, myocardial infarction, acute kidney injury, pulmonary oedema) during the hospital 
stay across all stroke types. Patients with HF who were admitted with AIS were more likely 
to be comatose in-hospital. Patients with HF and AIS were more likely to receive IV 
thrombolytic treatment than those without. 
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 All Strokes Acute Ischemic Stroke Intracerebral Hemorrhage Stroke of undetermined 
pathology 
 HF (n = 
15,397) 
No HF (n = 
593,493) 
HF (n = 
11,522) 
No HF (n = 
359,005) 
HF (n = 
2464) 
No HF (n = 
170,772) 
HF (n = 
1411) 
No HF (n = 
63,716) 
Age 66.97 
(13.81) 
64.22 
(13.71) 
67.49 
(13.70) 
65.47 
(13.24) 
63.69 
(14.08) 
61.12 
(14.28) 
68.46 (1.40) 65.47 
(13.41) 
Sex  
 M 
   
 F 
 
6989 
(45.40%) 
8408 
(54.61%) 
 
328,328 
(55.32%) 
265,165 
(44.68%) 
 
5174 
(44.91%) 
6348 
(55.09%) 
 
192,553 
(53.64%) 
166,452 
(46.36%) 
 
1204 
(48.86%) 
1260 
(51.14%) 
 
102,204 
(59.85%) 
68,568 
(40.15%) 
 
611 
(43.30%) 
 
800 
(56.70%) 
 
33,571 
(52.69%) 
30,145 
(47.31%) 
Length of Stay 6 (3-12) 3 (2-7) 6 (3-12) 3 (2-6) 7 (3-19) 5 (2-11) 4 (2-8) 3 (2-5) 
Co-morbidities at admission 
Hypertension 8398 
(54.54%) 
289539 
(48.79%) 
6037 
(52.40%) 
170207 
(47.41%) 
1660 
(67.37%) 
93184 
(54.57%) 
701 
(49.68%) 
26148 
(41.04%) 
Diabetes Mellitus 3565 
(23.15%) 
100563 
(16.94%) 
2729 
(23.69%) 
72705 
(20.25%) 
538 
(21.83%) 
16379 
(9.59%) 
298 
(21.12%) 
11479 
(18.02%) 
Dyslipidaemia 3859 
(25.06%) 
139704 
(23.54%) 
3180 
(27.60%) 
112032 
(31.21%) 
390 
(15.83%) 
15097 
(8.84%) 
289 
(20.48%)* 
12575 
(19.74%)* 
Ischemic Heart 
Disease 
2400 
(15.59%) 
16161 
(2.72%) 
1861 
(16.15%) 
12196 
(3.40%) 
289 
(11.73%) 
2251 
(1.32%) 
250 
(17.72%) 
1714 
(2.69%) 
Valvular Disease 1626 
(10.56%) 
8746 
(1.47%) 
1326 
(11.51%) 
7022 
(1.96%) 174 (7.06%) 862 (0.50%) 126 (8.93%) 862 (1.35%) 
Atrial Fibrillation 5075 
(32.96%) 
35173 
(5.93%) 
4230 
(36.71%) 
29240 
(8.14%) 
453 
(18.38%) 
2973 
(1.74%) 
392 
(27.78%) 
2960 
(4.65%) 
Arrhythmia 
421 (2.73%) 
4374 
(0.74%) 331 (2.87%) 
3259 
(0.91%) 55 (2.23%) 657 (0.38%) 35 (2.48%) 458 (0.72%) 
Peripheral Vascular 
Disease 108 (0.70%) 
1486 
(0.25%) 85 (0.74%) 
1067 
(0.30%) 16 (0.65%) 316 (0.19%) 7 (0.50%) 103 (0.16%) 
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Cancers 103 
(0.67%)* 
3136 
(0.53%)* 89 (0.77%)* 
2094 
(0.58%)* 10 (0.41%)* 
753 
(0.44%)* 4 (0.28%)* 
289 
(0.45%)* 
Chronic Obstructive 
Pulmonary Disease 756 (4.91%) 
10131 
(1.71%) 563 (4.89%) 
6856 
(1.91%) 107 (4.34%) 
2126 
(1.24%) 86 (6.09%) 
1149 
(1.80%) 
Chronic Kidney 
Disease 
2085 
(13.54%) 
31173 
(5.25%) 
1549 
(13.44%) 
21167 
(5.90%) 
355 
(14.41%) 
6850 
(4.01%) 
181 
(12.83%) 
3156 
(4.95%) 
Liver Disease 
307 (1.99%) 
7302 
(1.23%) 222 (1.93%) 
3597 
(1.00%) 62 (2.52%)* 
3149 
(1.84%)* 23 (1.63%) 556 (0.87%) 
Anaemia 2190 
(14.22%) 
39809 
(6.71%) 
1547 
(13.43%) 
22748 
(6.34%) 
476 
(19.32%) 
14071 
(8.24%) 
167 
(11.84%) 
2990 
(4.69%) 
Alcohol-related 
disorders 92 (0.60%) 
7129 
(1.20%) 66 (0.57%) 
3151 
(0.88%) 22 (0.89%) 
3485 
(2.04%) 4 (0.28%)* 
493 
(0.77%)* 
Neurodegenerative 
disorders 251 (1.63%) 
5811 
(0.98%) 213 (1.85%) 
4695 
(1.31%) 18 (0.73%) 607 (0.36%) 20 (1.42%)* 
509 
(0.80%)* 
 
Table 1. Patient characteristics and co-morbid conditions at hospital admission. Continuous normally disitributed variables (Age) are presented 
as mean (SD), whilst continuous non-normal variables (length of stay) are presented as median (inter-quartile range). Categorical variables are 
presented as frequency (percentage). All between-group differences are statistically significant (P < 0.01) unless otherwise specified. 
*Between-group difference not statistically significant (P > 0.01). 
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 All Strokes Acute Ischemic Stroke Intracerebral Hemorrhage Stroke of undetermined 
pathology 
 HF (n = 
15,397) 
No HF (n = 
593,493) 
HF (n = 
11,522) 
No HF (n = 
359,005) 
HF (n = 
2464) 
No HF (n = 
170,772) 
HF (n = 
1411) 
No HF (n = 
63,716) 
Admission parameters 
Fever 
147 (0.95%) 
4214 
(0.71%) 
102 
(0.89%)* 
2646 
(0.74%)* 27 (1.10%)* 
1121 
(0.66%)* 18 (1.28%)* 
447 
(0.70%)* 
Hyperglycaemia 
231 (1.50%) 
7328 
(1.23%) 
179 
(1.55%)* 
4936 
(1.37%)* 30 (1.22%)* 
1834 
(1.07%)* 22 (1.56%)* 
558 
(0.88%)* 
Hypoglycaemia 
360 (2.34%) 
6958 
(1.17%) 291 (2.53%) 
4683 
(1.30%) 39 (1.58%) 
1544 
(0.90%) 30 (2.13%) 731 (1.15%) 
In-hospital complications 
Death 3766 
(24.46%) 
84645 
(14.26%) 
2602 
(22.58%) 
28357 
(7.90%) 
989 
(40.14%) 
52850 
(30.95%) 
175 
(12.40%) 
3438 
(5.40%) 
Recurrent stroke 26 1238 17 696 6 378 3 164 
Respiratory Failure 3041 
(19.75%) 
53090 
(8.95%) 
2305 
(20.01%) 
21440 
(5.97%) 
595 
(24.15%) 
29977 
(17.55%) 141 (9.99%) 
1673 
(2.63%) 
Pneumonia 3088 
(20.06%) 
43936 
(7.40%) 
2281 
(19.80%) 
21845 
(6.08%) 
613 
(24.88%) 
19620 
(11.49%) 
194 
(13.75%) 
2471 
(3.88%) 
Sepsis 1161 
(7.54%) 
17061 
(2.87%) 881 (7.65%) 
9996 
(2.78%) 195 (7.91%) 
5878 
(3.44%) 85 (6.02%) 
1187 
(1.86%) 
Shock 
429 (2.79%) 
4537 
(0.76%) 347 (3.01%) 
1964 
(0.55%) 57 (2.31%) 
2309 
(1.35%) 25 (1.77%) 264 (0.41%) 
Myocardial Infarction 
777 (5.05%) 
2139 
(0.36%) 619 (5.37%) 
1600 
(0.45%) 101 (4.10%) 389 (0.23%) 57 (4.04%) 150 (0.24%) 
Acute Kidney Injury 1790 
(11.63%) 
18717 
(3.15%) 
1408 
(12.22%) 
12587 
(3.51%) 
268 
(10.88%) 
4881 
(2.86%) 114 (8.08%) 
1249 
(1.96%) 
Coma 
101 (0.66%) 
2532 
(0.43%) 67 (0.58%) 
1194 
(0.33%) 23 (0.93%)* 
1114 
(0.65%)* 11 (0.78%)* 
224 
(0.35%)* 
Pulmonary Oedema 184 (1.20%) 644 (0.11%) 121 (1.05%) 341 (0.09%) 48 (1.95%) 263 (0.15%) 15 (1.06%) 40 (0.06%) 
In-hospital procedures  
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Mechanical 
Ventilation 
4912 
(31.90%) 
114710 
(19.33%) 
3412 
(29.61%) 
42179 
(11.75%) 
1274 
(51.70%) 
68272 
(39.98%) 
226 
(16.02%) 
4259 
(6.68%) 
Tracheostomy 
858 (5.57%) 
20028 
(3.37%) 488 (4.24%) 
5364 
(1.49%) 
336 
(13.64%) 
14151 
(8.29%) 34 (2.41%) 513 (0.81%) 
Gastrostomy 3 (0.02%)* 89 (0.01%)* 3 (0.03%)* 44 (0.01%)* 0 (0.00%)* 38 (0.02%)* 0 (0.00%)* 7 (0.01%)* 
Thrombolysis 
302 (2.62%) 
5776 
(1.61%) 302 (2.62%) 
5776 
(1.61%) NA NA NA NA 
Echocardiography 1619 
(10.52%) 
14217 
(2.40%) 
1426 
(12.38%) 
12008 
(3.34%) 115 (4.67%) 
1427 
(0.84%) 78 (5.53%) 782 (1.23%) 
 
Table 2. Admission parameters, in-hospital complications and procedures. All variables are presented as frequency (percentage). All between-
group differences are statistically significant (P < 0.01) unless otherwise specified. 
*Between-group difference not statistically significant (P > 0.01). 
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Analysis of in-hospital mortality 
 The results of the multivariable logistic regressions with in-hospital death as the 
outcome are illustrated in Table 3. Pre-existing HF was associated with increased odds of in-
hospital death in all 4 models. Overall, there was an increase in odds, whilst the models fitted 
separately for each stroke type showed the biggest effect in AIS followed by strokes of 
undetermined pathology and ICH. 
 
 Death in hospital 
 OR [99%CI] P value 
All strokes 1.74[1.65-1.83] < 0.001 
Acute Ischemic Stroke 2.26[2.12-2.41] < 0.001 
Intracerebral 
Haemorrhage 1.39[1.24-1.55] < 0.001 
Stroke of undetermined 
pathology 1.75[1.40-2.20] < 0.001 
 
Table 3. Influence of pre-existing Heart Failure on stroke mortality in hospital (results of 
multivariable logistic regression with no HF as reference category; adjusted for the co-
variates shown in Supplementary Tables 1 & 2.). Results in bold are statistically significant 
(P < 0.01). 
 
 
 
Analysis of long-term post-discharge mortality  
 All patients were followed up for a maximum 4108 days for this outcome. Patients 
with ischaemic, haemorrhagic and undetermined strokes were followed up for a median (95% 
CI) of 1518 (1511-1525), 1731 (1715-1745) and 2409 (2385-2431) days, respectively. 
Supplementary Table 2 details the predictors which were included in each model and those 
that were introduced as time-varying covariates. Co-morbid HF was significantly associated 
with an excess mortality risk in all the stroke categories, as well as overall. For strokes of 
undetermined pathology, the HR [99%CI] was 2.01[1.88-2.15], whilst for AIS HR = 
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1.97[1.92-2.03]. Because the HR was calculated for ICH patients using RCS, the resulting 
function was not constant with time, and is illustrated in Supplementary Figure 1. This 
estimate is significant throughout most of the follow-up period. The HR becomes significant 
on the 13th day post-discharge HR (t=13) = 1.31[1.04-1.64], after which it increases to a 
maximum at the end of the follow-up period HR (t = 4108) = 2.56[2.03-3.22]. 
 Supplementary Figure 2 and Supplementary Table 3 illustrate the predicted survival 
functions stratified by HF status and stroke type. Overall, the survival rate is about half for 
those with HF who survived the index stroke compared to their counterparts without HF.  
 
Analysis of long-term post-discharge mortality and recurrence 
 For both mortality and recurrence, all patients were followed-up for a maximum of 
4108 days. For the mortality outcome, patients with ischaemic and haemorrhagic strokes 
were followed up for a median (95%CI) of 1583 (1577-1590) and 1802 (1792 – 1814) days, 
respectively. For the recurrent stroke outcome, patients with ischaemic and haemorrhagic 
strokes were followed up for a median (95%CI) of 875 (862 – 887) and 778 (767 – 789), 
respectively. Median follow-up times and 95% confidence intervals were calculated using the 
reverse Kaplan-Meier method. Supplementary Figure 3 illustrates the first-ever stroke patient 
population, stratified by stroke type. A total of 302,603 first AIS patients survived to hospital 
discharge without a recurrent event. Recurrent AIS occurred in 32,036 patients (10.59%). A 
total of 128,850 (42.58%) patients died during follow-up, 112,073 (37.04%) after their first-
ever stroke and 16,777 (5.54%) after their recurrent AIS. We recorded 96,060 first-ever ICH 
patients who survived to hospital discharge without having experienced stroke recurrence. 
Recurrent ICH occurred in 7548 (7.86%) patients. A total of 45,335 (47.19%) patients died 
during follow-up, 40,609 (42.27%) after their first-ever ICH, and 4726 (4.92%) after their 
recurrent bleed.  
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 Supplementary Table 4 displays the variables included in the models constructed for 
each transition and those that were introduced as time-updated variables.  
Supplementary Figure 4, Supplementary Table 5 and Figure 3 illustrate the predicted 
recurrence-free survival, recurrence and mortality probabilities stratified by HF status and 
stroke type. Supplementary Table 6 illustrates the follow-up post-discharge time when the 
maximum recurrence probability is reached and its value stratified by HF status and stroke 
type. 
Supplementary Table 7 and Figure 4 illustrate the HRs for each transition for each 
stroke type, calculated for patients with co-morbid HF (with no HF as reference). For AIS 
patients the HR function for recurrence was not statistically significant throughout the follow-
up period. In the AIS cohort, the HR for recurrence-free mortality was 1.69[1.64-1.74]. For 
post-recurrence death, HR = 1.45[1.34-1.57]. In ICH patients, the HR function for the 
recurrence outcome was not statistically significant except for the period between the 157th 
and the 1158th days post-discharge. The maximum value of the HR during this period was 
HR (t=387) = 1.79[1.18-2.73]. For the recurrence-free mortality outcome, the HR function 
was not significant for the first 89 days post-discharge. Following this period, the value of the 
HR function increases constantly to a maximum of HR (t=4108) = 2.59[2.07-3.26] at the end 
of the period. HF was not associated with post-ICH mortality: HR = 1.28[0.99-1.66]. 
The results of our sensitivity analyses with limited adjustments yielded similar results 
(Supplementary Figure 5). HF was not associated with AIS recurrence. The HR for post-AIS 
death was higher, HR = 2.01 [1.95-2.07]. The association between HF and ICH recurrence 
was significant between the 31st and 1130th days after discharge, reaching a maximum of HR 
(t=360) = 1.84[1.22-2.77]. The association between HF and post-ICH death was significant 
throughout the follow-up period: the HR function starts from a value of HR (t=7) = 
1.31[1.03-1.67] immediately after discharge and increases constantly until it reaches a plateau 
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at around 1.5 years after discharge HR (t=449) = 2.43[2.06-2.86]. The function then increases 
constantly until the end of the follow-up period HR (t=4108) = 2.98[2.37-3.75]. 
 
  
DISCUSSION 
Our findings indicate that HF predicts worse mortality outcomes in-hospital and 
during the long-term follow-up, both before and after stroke recurrence. However, certain 
important differences between AIS and ICH patients exist. In ICH, HF was not associated 
with an increased risk of post-discharge death in the very short follow-up (before ~3 months). 
After this period, the increased risk of death associated with a HF diagnosis was higher for 
ICH than AIS patients. Comparing the recurrence-free survival probabilities of ICH patients 
with and without HF, it becomes apparent that these results may arise from the high mortality 
of ICH patients in the short-term post-discharge period. Our analysis suggests that HF seems 
to influence outcomes only after ICH patients stabilize and their mortality rate decreases. It 
has been well recognized that intracranial haemorrhagic events can cause serious cardiac 
side-effects [14], including cardiac failure. It may thus be that ICH patients with co-morbid 
HF may be more likely to suffer cardiac decompensation, leading to an increased risk of 
death.   
Our statistical models yielded no association between HF and AIS recurrence. HF was 
associated with recurrent ICH only within the first 18 months. This revealed that there may 
be a ‘window’ within the first 30 months post-discharge when HF patients with ICH have an 
increased risk of both recurrent stroke and death, after which only the mortality risk persists. 
It is possible that the observed changes in the significance of ICH recurrence, 
occurring at around 2.5 years post-discharge, may be attributable to the contribution of more 
severe stroke types. As the patients with a more severe clinical presentation leave the cohort 
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(as they die) at ~ 2 years post-discharge, it is likely that this effect diminishes and thus the 
HR becomes insignificant. Nevertheless, in the absence of an objective measure of stroke 
severity, our hypothesis cannot be tested. Future work focusing on the impact of HF on stroke 
outcomes should therefore account for both stroke and HF severity. 
The relationship between HF and post-AIS mortality has been previously studied [1, 
4-8, 14-20], showing that the co-existent HF increases the mortality risk both in-hospital [5-8, 
15] and after discharge [4-8, 16-20].  
A previous meta-analysis [1] suggests that there is a two-fold increase in the risk of 
AIS recurrence associated with co-morbid HF. Nevertheless, our results appear to show that 
patients with HF were not at a higher risk of recurrent AIS than those without. Whilst this is 
based on observational data, our results appear to point into a similar direction as the recent 
COMMANDER HF trial, which showed that rivaroxaban anticoagulation was not associated 
with a reduction in the rate of stroke in heart failure patients [21]. 
The data regarding the influence of co-morbid HF on post-ICH mortality is scarce 
[22]. We have shown that the impact of HF on ICH mortality is substantial, with a two-fold 
mortality risk increase. Since previous studies on ICH recurrence [23, 24] have only focused 
on the radiological characteristics of the primary event, we are the first to evaluate the 
influence of co-morbid HF on ICH recurrence in the long-term.  
The mechanisms behind the association between HF and ICH recurrence remain 
nevertheless unclear. It may simply be that HF patients are more likely to receive anti-
thrombotic therapy [2] due to underlying co-morbidities (coronary artery disease, valvular 
disease and atrial fibrillation), thus rendering these patients more prone to haemorrhagic 
events [25, 26]. Whilst we were unable to explore this further in the current analysis, our 
results suggest that caution should be exerted with HF management strategies that may cause 
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haematological disturbances in patients with ICH. A balanced risk-vs-benefit approach may 
thus be desirable in the first 18 months after the acute event.  
Our study has several strengths. We have utilized a prospectively-identified multi-
centre national cohort, thus minimising the potential selection bias. To the best of our 
knowledge, this is the first study to differentially analyse the relationship between HF and 
long-term outcomes of AIS and ICH. Our analysis provides granular insight regarding the 
dynamic nature of the HF-associated increased risk of death and event recurrence. This has so 
far not been possible in previous studies. By employing multi-state survival methods and 
modelling the transition probabilities using flexible parametric techniques, we have managed 
to overcome the limitations of classical survival analysis models [27]. Furthermore, we have 
also estimated the absolute probabilities of recurrence-free survival, recurrence and death for 
both AIS and ICH, stratified by the HF status. By updating any post-discharge HF diagnoses 
in our statistical models, we have more accurately captured the real distribution of this co-
morbidity in our population. We have for the first time illustrated the time-varying nature of 
the excess mortality and recurrence risk associated with co-morbid HF in both stroke types. 
We are the very first study assessing the relationship between HF and cerebrovascular disease 
in Asians, population in which stroke epidemiology is markedly different [28, 29]. 
 We acknowledge certain limitations. Having based all of our analyses on insurance 
data, case ascertainment was performed using ICD10 codes. We thus lack data regarding 
stroke severity and the clinical characteristics of HF (severity, ejection fraction, aetiology). 
Given that stroke severity may be an important determinant of post-stroke prognosis, it may 
be not be possible to confirm a direct relationship between HF and adverse stroke outcomes. 
Furthermore, our data may not be applicable in other populations and different healthcare 
systems. It is important to underline that our cohort was significantly younger than Western 
stroke cohorts [5-8].  Nevertheless, the pathophysiological link between HF and stroke is 
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unlikely to be significantly different, highlighted by the fact that our results are concordant 
with previous literature. Our cohort enrolment occurred over 12 years and time-dependent 
differences may exist in case ascertainment and management. Nevertheless, this remains one 
of the inherent limitations of long-term follow-up studies. Our data did not include any 
information regarding post-discharge medications or ancillary procedures and we were thus 
unable to explore the effect of HF therapy or antithrombotic medication on outcomes. 
Finally, we were not able to evaluate the causes of death. 
In summary, we report for the first time the impact of co-morbid HF on the clinical 
trajectories of acute stroke patients, providing stroke-type specific prognostic information. 
We have shown that co-morbid HF significantly increases the risk of in-hospital and post-
discharge death in both AIS and ICH, with the effect on ICH patients being more 
pronounced. Whilst HF was not associated with AIS recurrence, it was associated with ICH 
recurrence in those surviving beyond 4 months (2 folds increase in RR) within first 30 
months.  The cautious use of antithrombotic agents may be advised in HF patients with ICH 
who remain at a high risk of recurrent events within first 30 months of the acute 
haemorrhagic event. 
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FIGURE LEGENDS 
Figure 1. Transitions used in creating the multistate models.  
Figure 2. Patient population flowchart.  
Figure 3. Stacked graphs showing the predicted probabilities of being in each state (recurrence-free 
survival, recurrence and mortality) stratified for HF status. Separate calculations were performed for each 
stroke type. 
Figure 4.  Hazard Ratio (HR) functions plotted against the post-discharge follow-up time. The solid line 
represents the point estimate, whilst the shaded area is bound by the limits of the 99% confidence interval. 
The dashed line represents the reference line (HR = 1). 
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Supplementary Data 
Disease classification ICD 10 code 
Acute Ischaemic Stroke I63; I63.0; I63.1; I63.2; I63.3; I63.4; I63.5; I63.6; I63.8; 
I63.9 
Intracerebral Haemorrhage I61; I61.0; I61.1; I61.2; I61.3; I61.4; I61.5; I61.6; I61.8; 
I61.9 
Stroke of undetermined pathology I64 
Heart Failure I25.5; I42.0; I42.9; I50; I50.0; I50.1; I50.9; I51.7 
Hypertension I10; I11.0; I11.9; I12.0; I12.9; I15.1; I15.2; I15.8; I15.9;  
Diabetes Mellitus E10.9; E11.0; E11.2; E11.3; E11.4; E11.5; E11.6; E11.8; 
E11.9 
Dyslipidaemia E75.6; E78.0; E78.1; E78.2; E78.3; E78.4; E78.5; E78.6; 
E78.8; E78.9 
Ischaemic Heart Disease I20.0; I20.9; I25.0; I25.1; I25.2; I25.8; I25.9 
Valvular Disease I06.2; I061; I060; I05.2; I05.9; I05.1; I05.0; I07.1; I08.0; 
I08.1; I08.3; I09.9; I35.1; I35.2; I35.0; I34.2; I34.0; I34.1 
Atrial Fibrillation I48 
Arrhythmia I49.0; I49.1; I49.3; I49.4; I49.5; I49.8; I49.9; R00; R00.0; 
R00.1; R00.2 
Peripheral Vascular Disease I70.1; I70.2; I70.8; I70.9; I71.0; I71.2; I71.4; I71.9; I72.9; 
I73.9; I74.2; I74.3; I74.9; I77.1; I77.6 
Cancers C11.9; C18.9; C20; C22.0; C22.1; C34.9; C50.9; C53.9; 
C61; C67.9; C73; C77.9; C78.2; C79.3; C79.5; C79.8 
Chronic Obstructive Pulmonary 
Disease 
J42; J43.9; J44; J44.0 
Chronic Kidney Disease N18; N18.0; N18.1; N18.2; N18.3; N18.4; N18.5; N18.9; 
N19; Z99.2 
Liver Disease K70.1; K70.3; K71.2; K71.6; K72.0; K72.9; K74.6; K75.0; 
K75.8; K75.9; K76.0; K76.9; R18 
Anaemia D50.0; D50.8; D50.9; D52.9; D53.1; D53.9; D61.9; D62; 
D63; D63.0; D63.1; D63.8; D64.8; D64.9 
Alcohol-related disorders F10.0; F10.1; F10.2; F10.20 
Neurodegenerative disorders F03; F03.0; G31.0; G31.1; G31.9 
Fever R50.8; R50.9 
Hyperglycaemia R73.0; R73.9 
Hypoglycaemia E16.1; E16.2 
Respiratory Failure J96; J96.0; J96.1; J96.9 
Pneumonia J13; J14; J15; J15.0; J15.1; J15.2; J15.4; J15.5; J15.6; J15.8; 
J15.9; J18; J18.0; J18.1; J18.2; J18.8; J18.9; J22 
Sepsis A02.1; A40.1; A40.8; A40.9; A41; A41.0; A41.1; A41.2; 
A41.5; A41.8; A41.9; B37.7; E02; R65.2 
Shock R57; R57.0; R57.1; R57.8; R57.9 
Myocardial Infarction I21; I21.0I21.4; I21.1; I21.2; I21.3; I22.9; I24.9 
Acute Kidney Injury N10; N17; N17.0; N17.8; N17.9 
Coma E15; R40.2 
Pulmonary Oedema J81 
 
Procedure ICD 9 code 
Mechanical Ventilation 9390; 9670; 9671; 9672 
Tracheostomy 311; 3129 
Gastrostomy 4311 
Thrombolysis 9910 
Echocardiography 8872 
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Supplementary Table 1. International Classification of Disease codes utilised in extracting the data regarding the 
listed co-morbidities, complications and procedures from the insurance database. 
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 Acute Ischaemic 
Stroke 
Intracerebral 
Haemorrhage 
Stroke of 
undetermined 
pathology 
Age    
Sex *  * 
Heart Failure  **  
Hypertension *  * 
Diabetes Mellitus * * * 
Dyslipidaemia    
Ischaemic Heart Disease   * 
Valvular disease    
Atrial Fibrillation    
Arrhythmias  * * 
Peripheral Vascular 
Disease    
Cancers    
Chronic Obstructive 
Pulmonary Disease    
Chronic Kidney Disease    
Liver Disease    
Anaemia    
Alcohol-related disorders * * * 
Neurodegenerative 
disorders  *  
Fever  *  
Hyperglycaemia *   
Hypoglycaemia  *  
 
Supplementary Table 2. Co-variates included in the multivariable models with the outcome of long-term mortality.*Variable was found to be non-
concordant with the proportional hazards assumption and was modelled as a non-constant function of time using the Weibull distribution. ** Variable was 
found to be non-concordant with the proportional hazards assumption and was modelled as a non-constant function of time using restricted cubic splines with 
5 degrees of freedom. 
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 HF (10 year - Survival [99%CI]) No HF (10 year -Survival 
[99%CI]) 
Ischaemic 17.92% [17.24% - 18.63%] 37.28% [36.93% - 37.65%] 
Haemorrhagic 18.87% [16.63% - 21.41%] 38.6% [38.07% - 39.08%] 
Undetermined 15.72% [14.30% - 17.27%] 34.78% [34.15% - 35.42%] 
 
Supplementary Table 3. Predicted values of the survival functions (presented as point estimates and 99% confidence interval values) for stroke type 
calculated for patients with and without co-morbid HF. 
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Stroke Type Acute Ischaemic Stroke Intracerebral Haemorrhage 
Transition Baseline 
– 
Recurrent 
stroke 
Baseline-
Death 
Recurrent 
stroke - 
Death 
Baseline 
– 
Recurrent 
stroke 
Baseline-
Death 
Recurrent 
stroke - 
Death 
Age *   *  * 
Sex * * *    
Heart Failure **   ** **  
Hypertension * * * *  * 
Diabetes Mellitus * * * * * * 
Dyslipidaemia    *  * 
Ischaemic Heart 
Disease *  * * 
  
Valvular disease       
Atrial Fibrillation    *   
Arrhythmias   * * *  
Peripheral Vascular 
Disease *  * * 
 * 
Cancers *  * *   
Chronic Obstructive 
Pulmonary Disease *  * * 
 * 
Chronic Kidney 
Disease *   * 
  
Liver Disease *  * *  * 
Anaemia *   * * * 
Alcohol-related 
disorders *  * * 
* * 
Neurodegenerative 
disorders *   * 
* * 
Fever *   * * * 
Hyperglycaemia * *  *  * 
Hypoglycaemia *  * * * * 
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Supplementary Table 4. Co-variates included in the transition multivariable models used to construct the multistate statistical model 
*Variable was found to be non-concordant with the proportional hazards assumption and was modelled as a non-constant function of time using the Weibull 
distribution.  
** Variable was found to be non-concordant with the proportional hazards assumption and was modelled as a non-constant function of time using restricted 
cubic splines with 5 degrees of freedom. 
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 10-year Recurrence Free Survival 10-year recurrence probability 10-year Mortality probability 
 HF No HF HF No HF HF No HF 
Ischaemic 15.27%[13.98%-16.47%] 
28.21%[27.05%-
53.46%] 
2.91%[2.41%-
3.57%] 
4.19%[3.67%-
5.70%] 
81.72%[80.41%-
83.12%] 
67.65%[66.24%-
43.69%] 
Haemorrhagic 12.01%[9.03%-15.26%] 
24.73%[23.18%-
41.42%] 
1.08%[0.58%-
1.72%] 
2.30%[1.88%-
3.16%] 
86.88%[83.54%-
89.79%] 
72.96%[71.34%-
59.07%] 
Supplementary Table 5.  Probability of recurrence-free survival, recurrence and mortality at 10 years and the 99% confidence interval for each stroke type, 
stratified by HF status. 
 
 HF No HF 
 Follow-Up Time (days) P [99% CI] 
Follow-Up Time 
(days) P [99% CI] 
Ischaemic 1579 4.46%[3.87%-5.02%] 1747 5.25%[4.72%-5.82%] 
Haemorrhagic 404 2.72%[1.90%-3.68%] 45 3.12%[2.60%-3.58%] 
Supplementary Table 6. Maximum probability of recurrence for each stroke type and day of follow-up when achieved, stratified by HF status. 
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 AIS ICH 
Transition HR[99% CI] HR[99% CI] 
Baseline – Recurrent 
stroke * * 
Baseline – death 1.54 [1.48-1.61]] * 
Recurrent stroke – 
death  1.27 [1.16-1.40] 1.46 [1.14-1.88] 
 
*Hazard Ratio modelled as a function of time due to non-concordance with the proportional hazard assumption. Graph of the function illustrated 
in Figure 6 
Supplementary Table 7. Hazard Ratios of each transition, calculated for patients with HF (with no HF as reference). 
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Supplementary Figure 1. The hazard ratio (HR) calculated for patients with intracerebral 
haemorrhage and co-morbid heart failure (with no heart failure as the reference category). 
The solid line represents the point estimate, whilst the shaded area is bound by the extreme 
values of the 99% confidence interval
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Supplementary Figure 2. Predicted survival probability stratified by HF status. Separate calculations were performed for each stroke type. The solid line 
represents the point estimates in patients without co-morbid heart failure, whilst the dashed line represents the point estimates in patients with co-morbid heart 
failure. The shaded areas are bound by the extreme values of the 99% confidence interval for each respective point estimate 
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Supplementary Figure 3. Flowchart of first-ever stroke patients admitted with Acute 
Ischemic Stroke (AIS) and Intracranial Haemorrhage (ICH) respectively.
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Supplementary Figure 4. Predicted probabilities of being in each state (recurrence-free 
survival, recurrence and mortality) stratified for HF status. Separate calculations were 
performed for each stroke type. The solid line represents the point estimates in patients 
without co-morbid heart failure, whilst the dashed line represents the point estimates in 
patients with co-morbid heart failure. The shaded areas are bound by the extreme values of 
the 99% confidence interval for each respective point estimate. 
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Supplementary Figure 5. Results of the sensitivity multi-state analysis adjusting only for 
cardiovascular co-morbidities. Hazard Ratio (HR) functions were plotted against the post-
discharge follow-up time. The solid line represents the point estimate, whilst the shaded area 
is bound by the limits of the 99% confidence interval. The dashed line represents the 
reference line (HR = 1).
 
 
 
 
 
 
